Central nervous system (CNS) replapse in patients with diffuse large B cell lymphoma (DLBCL) is an uncommon event and often confers a poor prognosis, Estimates of incidence vary from 1.9-6.4% with discrepancy in the literature as to whether the introduction of rituximab has reduced this risk (Boehme, et al 2009, Gleeson, et al 2017,Mitrovic, et al 2012, Villa, et al 2010.

 

Declaration of Interests

The BSH paid the expenses incurred during the writing of this guidance. None of the authors had conflicts of interest to declare. All authors have made a declaration of interests to the BSH and Task Force Chairs which may be viewed on request.